Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with idiopathic PD.~2. At least 30 years old at the time of PD diagnosis.~3. Currently being treated with IR LD (CD-LD or benserazide-LD) and on a stable regimen of IR LD for at least 4 weeks and:~   * Requiring a total daily IR LD dose of at least 400 mg~  * Having a minimum dosing frequency of four times per day.~4. Able to differentiate on state from off state.~5. Have predictable off periods.~6. Amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists are allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.~7. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month afterward.~Exclusion Criteria:~1. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.~2. Nonresponsive to LD therapy.~3. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.~4. Received within 4 weeks or planning to take during participation in the clinical study: any controlled-release LD product, additional CD (e.g., Lodosyn®) or benserazide (e.g. Serazide®), catechol-O-methyl transferase inhibitors (e.g., entacapone and tolcapone), nonselective MAO inhibitors, apomorphine, and antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.~5. Allergic to Yellow Dye #5 (tartrazine).~6. History of or currently active psychosis.~7. Active or prior medical conditions such as peptic ulcers or prior surgical (e.g., bowel) procedures that would interfere with LD absorption.~8. Active or history of narrow-angle glaucoma.~9. A history of malignant melanoma or a suspicious undiagnosed skin lesion.~10. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.~11. Received any investigational medications during the 4 weeks prior to Screening.~12. Unable to swallow large pills (e.g., large vitamin pills).~13. Pregnant or breastfeeding.~14. Subjects who are unable to complete a symptom diary.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPX066 (Type: EXPERIMENTAL): Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
- IR CD-LD (Type: ACTIVE_COMPARATOR): Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete